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Hemofiltration reduces the serum priming activity on neutro- Continuous hemofiltration is an important tool to con-
phil chemiluminescence in septic patients. trol uremia in patients suffering from acute renal failure
Background. Priming of the polymorphonuclear neutrophil (ARF) in the intensive care unit (ICU). Continuous hemo-(PMN) response has been implicated in the activation of oxida-
filtration results in fewer side effects and provides bettertive burst and tissue injury in patients with septic shock and
control of body fluids, electrolytes, and acid-base balanceacute renal failure (ARF). This study evaluated whether hemo-
filtration (HF) removes substances able to enhance the oxida- [1]. Furthermore, it has been suggested that continuous
tive burst of PMNs. veno-venous hemofiltration (CVVH) also favorably in-
Methods. Chemiluminescence (CL) priming activity induced
fluences the outcome of ARF septic patients by removingby sera and ultrafiltrates of seven patients with septic shock,
inflammatory substances that are important in the devel-multiorgan dysfunction syndrome, and ARF (ARF/HF group)
and of 10 uremic stable patients (Control/HF group) was evalu- opment of septic process [2–5].
ated on normal human PMNs stimulated with bacterial formyl- Inflammatory mediators produced during the immune
methionyl-leucyl-phenylalanine (FMLP). Patients submitted to and inflammatory reaction against infection include sev-HF were studied by determining blood and ultrafiltrate interleu-
eral factors that may activate circulating polymorpho-kin-8 (IL-8), platelet-activating factor (PAF), and CL priming
nuclear neutrophils (PMNs), such as interleukin-8 (IL-8),activity at the beginning (T0), and after four hours (T4) of treat-
ment. tumor necrosis factor (TNF), interleukin-1 (IL-1), colony
Results. Preincubation of normal human PMNs with sera and stimulating factor, platelet-activating factor (PAF), and
ultrafiltrates from septic patients induced a potent priming of
other eicosanoids [6]. These mediators act on circulatingCL activity in subsequent FMLP stimulation. In the ARF/HF
PMNs by stimulating the oxidative burst and/or exertinggroup, the prefilter blood concentrations of IL-8 and CL PMN-
priming activity significantly decreased during the four hours a priming effect to a secondary stimulus, such as bacterial
of HF treatment, with a loss of IL-8 in the ultrafiltrate of 6930 N-formyl peptides [7, 8]. Priming activity is important in
(median, range 4292 to 9282) ng per four hours. PAF detected PMN-mediated antimicrobial action and in tissue damage,in the ultrafiltrate and associated with the membrane (7.3 ng,
and several investigators have reported the priming ofrange 1.45 to 9.89) was minimal. In the ARF/HF group, a
PMNs in septic and injured patients [9–11]. Experimentalsignificantly positive correlation between CL PMN-priming ac-
tivity and IL-8 concentrations was observed. The CL priming and clinical evidence led to a two-hit model for the devel-
activity in blood and ultrafiltrates was reduced to 55 and 46% opment of multiorgan dysfunction syndrome (MODS)
by preabsorption with monoclonal antibody (mAb) anti-IL-8.
[12, 13]. In this model, an uncontrolled inflammatoryIn contrast, the PAF receptor antagonist WEB 2170 did not
injury is elicited by two sequential events: an initial eventaffect CL priming activity. In the control/HF group, the CL
PMN-priming activity was significantly lower than in the that primes the immune system, followed by a second
ARF/HF group and was independent of IL-8. stimulus causing an exaggerated inflammatory response.
Conclusions. Sera from septic patients demonstrate an en- Several studies suggest that PMNs are the main cellu-hanced CL priming activity on PMNs. This activity is reduced
lar target for priming activity of most cytokines that atby ultrafiltration and is due, at least in part, to ultrafiltered IL-8.
low concentration fail to induce oxygen radical produc-
tion or protease release, but when subsequently exposed
Key words: PMN oxidative burst, ultrafiltrate, septic shock, interleu-
to “activation stimuli” cause degranulation and oxidativekin-8, platelet-activating factor, acute renal failure, uremia, inflamma-
tion. burst activation. In clinical settings, the nature of priming
agents and of final effector molecules remains largely un-
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Several studies have investigated the effect of hemo- filtration session, the filters were disconnected from the
extracorporeal circuit, extensively washed with isotonicfiltration on the removal of inflammatory mediators [2–5].
However, no data are available on the influence of con- saline, emptied, and perfused with methanol from the
blood inlet (blood compartment) and from the ultrafil-tinuous hemofiltration on the PMN priming activity pres-
ent in sera of septic patients. trate ports (ultrafiltrate compartment).
The aim of the present study was to evaluate whether
Dialysis techniquehemofiltration removes substances able to enhance the
oxidative burst of neutrophils in septic patients. Our par- Hemofiltration was performed using highly permeable
polysulfone membrane (blood pump Multimat B IC orticular focus is on IL-8 and PAF, because these mediators
have been suggested to play a major role in priming Gambro AK10, blood flow at 200 mL/min with ultrafiltra-
tion rate at approximately 2.5 L/h, high permeability polys-activity in patients at risk of developing MODS [9, 14].
ulfone filter BL627; Bellco S.p.A., Mirandola, Modena,
Italy) with lactate- or bicarbonate-containing replace-
METHODS
ment fluid infused in a postdilution mode (SIF SoluBag
Study protocol BH496/B lactate 35 mmol/L or CB30 bicarbonate-30
mmol/L, SIFRA; Isola Della Scala, Verona, Italy). Hepa-The study protocol was approved by the local institu-
tional ethics committee. Seventeen patients were en- rinization was performed initially at 250 U/h or at the
lowest dose able to prevent clotting of the circuit. Vascularrolled for the study. Seven patients with septic shock
(aged 66.6  3.6 years, mean  SEM) with MODS de- access was obtained in the ARF/HF group by percutane-
ous double-lumen catheter via the subclavian/jugular veinfined according to criteria of the ACCP/SCCM Consen-
sus Conference [15] and acute renal failure (defined as a and in the control/HF group by arteriovenus fistula.
serum creatinine higher than 2.0 mg/dL and urine output
Isolation of human neutrophilslower than 20 mL/h despite volume correction and inten-
sive diuretic therapy) were submitted to a 24-hour ses- Human PMNs derived from healthy adult volunteers
were prepared as previously described [16]. Briefly, bloodsion of hemofiltration (ARF/HF group) for the treat-
ment of renal failure. As controls, after the informed was drawn into plastic tubes containing 5 mmol/L ethyl-
enediaminetetraacetic acid (EDTA) and centrifuged forconsent was obtained, 10 stable patients in regular dial-
ysis treatment (control/HF group) were submitted to 20 minutes at 700  g. Plasma and buffy coat were re-
moved, and pellets were resuspended in 2 volumes offour hours of hemofiltration in the same experimental
conditions of the ARF/HF group, except for the duration 2.5% gelatin (Difco Laboratories, Inc., Detroit, MI, USA)
in saline. The bulk of the erythrocytes were removed byof the treatment.
The blood and ultrafiltrate samples for PAF, IL-8, and low-speed centrifugation, and the remaining cells were
pelleted by centrifugation for 20 minutes at 700  g.chemilumescence (CL) measurements were obtained in
both the ARF/HF and control/HF groups after a steady- The cells were subjected to osmotic shock to eliminate
contaminating erythrocytes, and were washed twice withstate condition in the hemofiltration procedure was reached
(T0;10 minutes after connecting the lines to the patient) TT-BSA without Ca2 and Mg2. Smears of cells stained
with May-Gruenwald-Giemsa showed 85 to 95% PMN.and four hours after the beginning of treatment (T4).
Samples were taken simultaneously from the afferent The cells were resuspended at 107/mL in TT without Ca2
and Mg2 and were kept at 4C. Cell viability determinedblood line (prepump), from the efferent blood line after
the delivery of replacement fluid, and from the ultrafil- by Trypan Blue exclusion test was between 90 to 95%.
trate port. CL and IL-8 levels also were determined in
Chemiluminescencethe ultrafiltrates of the ARF/HF group at 6, 12, 18, and
24 hours after the treatment start. The sieving coefficient Luminol-enhanced CL was measured on purified hu-
man PMNs with a LKB Luminometer 1250 (LKB, Upp-(SC) of IL-8 was calculated according to the following
formula: SC 2*Cf/(Cpin  Cpout), where Cf is the ultra- sala, Sweden). In standard assays, 2106 cells at 37C
resuspended in HEPES-buffered Krebs medium contain-filtrate concentration, Cpin is the filter inlet plasma con-
centration, and Cpout is the filter outlet plasma concentra- ing 0.05% BSA (NaCl 119 mmol/L, KCl 4.75 mmol/L,
CaCl2 0.42 mmol/L, MgSO4 7 H2O 1.19 mmol/L, sodiumtion. All samples for CL study and IL-8 were stored in
fractions in polyethylene tubes at a temperature of phosphate buffer 16.6 mmol/L at pH 7.4, dextrose 5.56
mmol/L) with luminol 150 mol/L were added to each20C and thawed for the analysis.
Platelet-activating factor was studied both in ultrafil- vial (final volume 1.3 mL). In the priming experiments,
the cells were preincubated with ultrafiltrate 20 L ortrate (PAF-UF) and in blood, as platelet-associated (PAF-
Ptls) and as plasma concentration (PAF-Plsm). For the with serum 20 L for ten minutes and then stimulated
with N-formyl-methionyl-leucyl-phenylalanine (FMLP)determination of PAF associated with the dialysis mem-
branes (PAF-Filter), at the end of the four-hour hemo- 0.75 mol/L (Sigma Co., St. Louis, MO, USA). As con-
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trols, PMNs were incubated with 100 L of saline and Immunoassay of IL-8
FMLP 0.75 mol/L. In selected experiments performed The serum and ultrafiltrate concentrations of IL-8 were
with inhibitors of CL priming activity, we previously measured using an enzyme-linked immunosorbent assay
preincubated ultrafiltrate 100 L with PAF-receptor an- (ELISA, Quantikine; R&D Systems, Inc., Minneapolis
tagonist WEB2170 1mol/L (Boehringer Ingelheim, Ingel- MN, USA) according to the manufacturer’s suggestion.
helm/Rh, Germany) [17], with 100 g/mL of monoclonal All samples were tested in duplicate. The lowest concen-
antibody (mAb) anti human IL-8 (Sigma Co.) or with trations of detectable cytokine in the sample from the
100 g/mL mAb anti-human IL-10 (Sigma Co.). zero value were 18 pg/mL (serum) and 5 pg/mL (ultrafil-
Chemiluminescent PMN activity was expressed in trate) of IL-8. A single calibration curve for each type
mVolt, as area under the curve of the initial 10-minute of sample (serum and ultrafiltrate) was constructed. Sam-
CL signal from which the machine background had been ples below the detection limit were assumed to have
subtracted. Since absolute comparisons between samples a mean value between zero and the lowest detectable
were invalid because of the donor-dependent variability concentration.
of FMLP-stimulated CL activity, each sample was inde-
Statistical analysispendently evaluated as its own control and expressed as
the percentage variation. Statistical analyses for nonparametric data, including
Mann-Whitney test, Spearman’s correlation test, were
Purification and characterization of PAF performed using the software-package Statistica (Stat-
Soft, Tulsa, OK, USA). Values were expressed whenFresh blood (20 mL) and ultrafiltrate (10 mL) samples
appropriate as mean  SEM, as median with range, orobtained at each time point were immediately processed
median with 25th and 75th quartiles. P values 0.05for PAF extraction. Blood samples were collected in
were considered statistically significant.citric acid-dextrose solutions (ratio 1:6) and immediately
centrifuged at 200  g (20 min at 22C). Platelet-rich
plasmas were removed and centrifuged at 1000  g for RESULTS
20 minutes, while platelet pellets were resuspended and
FMLP is currently used as a secondary stimulus forwashed twice in a Ca2-Mg2–freeTris-Tyrode solutions.
PMN priming to evidence cooperation between endoge-In blood, PAF was measured as PAF-associated with
nous mediators and bacterial products, as PMNs expressplatelets (PAF-Ptls) or as PAF extracted from plasma
specific receptors for this bacterial peptide [20]. At the(PAF-Plsm).
concentration used in this study, FMLP was unable to
Lipid extraction was performed as previously de-
induce a PMN oxidative burst per se as detected by CL
scribed, with formic acid added to lower the pH of the (Fig. 1). The generation of CL by PMNs is dependent
aqueous phase to 3.0 [16]. on a complex relationship between cellular activation
Platelet-activating factor was assayed after extraction and a series of enzymatic and nonenzymatic reactions,
and purification by thin-layer chromatography (TLC; sil- ultimately resulting in the production of electronically
ica gel plates 60 F254; Merck, Darmstardt, Germany) excited state, which, in relationship to the ground state,
and high-pressure liquid chromatography (HPLC; mi- produces light. However, the yield of excited products
croPorasil column; Millipore Chromatographic Division, from dioxygenations of native substrate is low, and the
Waters, Milford, MA) by aggregation of washed rabbit substrates presented are numerous and vary with the
platelets as previously reported [16]. The biologically nature of stimulus. The addition of luminol in excess to
active material extracted from platelets and plasmas in the system avoids both these limitations [21, 22].
different samples was characterized by comparing syn- Preincubation of normal human PMNs with sera and
thetic PAF with the following criteria: (1) induction of ultrafiltrates from septic patients induced a potent prim-
platelet aggregation by a pathway independent both from ing of CL activity to subsequent FMLP stimulation (Fig.
the adenosine diphosphate (ADP) and arachidonic acid/ 1). Sera and ultrafiltrates alone were unable to induce
thromboxane A2-mediated pathways; (2) specificity of a direct CL activity on PMNs (Fig. 1).
platelet aggregation as inferred from the inhibitory effect We studied whether IL-8 and PAF, which are known
of 3 mol/L WEB 2170 (Boehringer Ingelheim) [17] and to stimulate CL activity [23–25], may account for the CL
5 mol/L CV-3988 (Takeda Chemical Industries, Kyoto, priming activity observed in sera and ultrafiltrates from
Japan) [18], two chemically unrelated PAF receptor an- septic patients.
tagonists; and (3) TLC and HPLC behavior and physico- As shown in Table 1, the prefilter and postfilter serum
chemical characteristics, such as inactivation by strong and ultrafiltrate concentrations of IL-8 were significantly
bases and by phospholipase A2 treatment, but resistance higher in septic patients (ARF/HF group) than in control
to phospholipase A1, acids, weak bases, and 5 minutes patients (control/HF group). The use of uremic patients
as the controls is limited in that sera of chronic renalof heating in boiling water [19].
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Fig. 1. Light emission by polymorphonuclear
neutrophils (PMNs; 2  106, in the presence
of luminol) after preincubation with serum (20
L for 10 minutes) or ultrafiltrate (20 L for
10 minutes) of septic patients treated by hemo-
filtration. After preincubation of samples with
serum or ultrafiltrate, luminol-added PMNs
were stimulated with FMLP (final concentra-
tion 0.75 mol/L). Chemiluminescence (CL)
was calculated as the integral of the first 10-
minute CL recording and was expressed as %
variation of each sample from its own control.
As a normal subject control, we studied on
PMNs CL priming activity of serum from
healthy volunteers. PMNs were preincubated
with healthy normal serum 20 L (for more
details; Methods section) and then stimulated
with FMLP 0.75 mol/L. Data obtained were
404  44% (N  7 volunteers). Values are
expressed as mean  SEM. Symbols are: ()
serum  FMLP; (····) ultrafiltrate  FMLP;
() serum alone; () ultrafiltrate alone; (––)
FMLP alone.
Table 1. Pre- and postfilter serum interleukin-8 (IL-8) concentrations at baseline (T0) and four hours (T4) in patients of
control/HF group and ARF/HF group failure
Time T0 pg/mL Time T4 pg/mL Ultrafiltrate
Prefilter Postfilter Prefilter Postfilter ng/4 h
Control/HF group (N  10) 9.0 (9–26) 9.0 (9–15) 9.0 (4.5–19) 9.0 (4.5–19) 26.0 (0–53)
ARF/HF group (N  7) 1260 (905–1945)ab 820 (450–1560)a 908 (540–1345)a 700 (395–1055)a 6930 (4242–9282)a
IL-8 in the ultrafiltrate is expressed as amounts ultrafiltered in 4 hours of hemofiltration. Values are given as median (with range). Abbreviations are: HF,
hemofiltration; ARF, acute renal failure.
a P  0.05, Mann-Whitney test between control/HF group and ARF/HF group
b P  0.05, Mann-Whitney test between T0 and at T4
failure patients may contain factors interfering in vitro treatment by hemofiltration for four hours significantly
with the function of normal human leukocytes. However, decreased CL priming activity of prefilter serum in the
the CL priming activity observed in control/HF sera was ARF/HF group, whereas no significant differences were
similar to that detected in sera of normal subjects (Fig. observed in the control/HF group (Fig. 3).
1). In the ARF/HF group, the prefilter blood concentra- A significantly positive correlation was found between
tions of IL-8 significantly decreased during the four hours the CL priming activity and the IL-8 concentrations in
of hemofiltration treatment (Table 1). In ARF/HF pa- the ultrafiltrates of the ARF/HF group (Fig. 4). Concen-
tients, the ultrafiltered IL-8 reached 6930 ng/4 h (range trations of IL-8 (10 to 4000 pg/mL) comparable to those
4242 to 9282), whereas it was minimal in the control/HF detected in the ultrafiltrates in vitro caused a potent
group (Table 1). The SC of IL-8 was 0.62 (range 0.52 to dose-dependent CL priming activity on PMNs, whereas
0.88) in the ARF/HF group and 0.26 (range 0 to 0.53) IL-8 alone was ineffective (Fig. 5). Pretreatment of IL-8
in the control/HF group.
with 100 g/mL of mAb anti human IL-8 completely
As shown in Figure 2, the amount of PAF-Ptls, PAF-
abrogated the IL-8–induced priming activity.Plsm, PAF-UF, and PAF associated with dialyzer mem-
The CL priming activity in ultrafiltrates (Fig. 6) andbranes (PAF-filter) was significantly higher in septic pa-
in blood of the ARF/HF group was significantly reducedtients than in uremic controls. However, the amount of
by preabsorption with mAb anti-IL-8. In contrast, thePAF detected in the ultrafiltrate of the ARF/HF group
CL priming activity was not decreased by pretreatmentwas minimal, and the blood concentrations of PAF did
of PMNs with the PAF receptor antagonist WEB 2170not decrease during four hours of treatment (Fig. 2).
or with mAb anti-IL-10 (Fig. 6). No significant changesFigure 3 shows that CL priming activity on PMNs of
in CL priming activity were observed in the ultrafiltratessera obtained pre- and postfilter and of ultrafiltrates was
of the control/HF group after treatment with mAb anti-significantly higher in septic patients of the ARF/HF
patients than in the control/HF group. Moreover, the IL-8, WEB 2170, or mAb anti-IL-10 (Fig. 6).
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Fig. 2. Blood, ultrafiltrate and filter-associ-
ated platelet-activating factor (PAF) before
and after four hours of treatment in the con-
trol/ARF and ARF/HF groups. A significant
amount of PAF was present in the blood and
filter-associated PAF in the ARF/HF group.
PAF was not detected in the ultrafiltrate. Data
are expressed as median with 25th and 75th
percentiles. Boxes enclose the interquartile
range and the median (open square in each
box), while whiskers enclose the range (min-
max values) Mann-Whitney test was performed
between control/HF group and ARF/HF group.
Symbols are: ( ) PAF-platelets ng/mL; ( )
PAF-plasma ng/mL; ( ) PAF-UF ng/4 h; ( )
PAF-filter ng/mL; *P  0.05.
Fig. 3. Chemiluminescence (CL) priming ac-
tivity on the PMNs of serum prefilter, serum
postfilter and of ultrafiltrates of the ARF/HF
and control/HF groups. PMNs were preincu-
bated with serum 20 L or ultrafiltrates 20 L
(details are in the Methods section) and then
stimulated with FMLP 0.75 mol/L. Data are
expressed as median with 25th and 75th per-
centile. Boxes enclose the interquartile range
and the median (open square in each box),
while whiskers enclose the range (min-max
values). Mann-Whitney test was performed be-
tween *P 0.05, ARF/HF group vs. control/HF
group, §P 0.05 T0 vs. T4 of the ARF/HF and
control/HF groups. Symbols are: ( ) serum
prefilter  FMLP; ( ) serum postfilter 
FMLP; ( ) ultrafiltrate  FMLP.
DISCUSSION human PMNs subsequently stimulated with FMLP, a
synthetic analogue of bacterial n-formyl peptides. Fur-The results of the present study demonstrate that he-
thermore, when patients were submitted to continuousmofiltration eliminates bioactive substances by a priming
hemofiltration, this priming activity became detectableactivity on PMNs in septic patients, and suggest that this
in the ultrafiltrates, suggesting that mediators responsi-activity is due, at least in part, to IL-8.
ble for this biological activity in serum also were presentDuring septic shock and acute renal failure, many pro-
in the ultrafiltrate. A number of mediators may contrib-inflammatory and anti-inflammatory substances (cyto-
ute to CL priming activity in septic patients. We focusedkines, eicosanoids, peptides) are present in high concen-
on the possible involvement of PAF and IL-8, two in-trations in serum [2–5, 9, 26, 27]. Some of these substances
flammatory mediators implicated in the pathogenesis ofcooperate in the priming of circulating inflammatory
human septic shock [28, 29] and capable of exerting acells, and either increase the host defense to infection
potent priming activity on PMNs [8, 23–25, 30–32]. Inor contribute to tissue injury [6, 9]. PMNs, once primed,
patients with septic shock and acute renal failure, bloodare able to respond maximally to a subsequent stimulus,
and urinary concentrations of PAF significantly corre-such as that provided by bacterial protein n-formyl pep-
lated with the degree of renal impairment and of renaltides [8, 20, 23–25].
inflammatory injury [33]. The rate of metabolism of PAFThe present study found that sera and ultrafiltrates of
septic patients had an important CL priming activity on to its inactive metabolites was reduced in concomitance
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Fig. 4. Relationship between UF concentra-
tions of IL-8 and CL priming activity on PMNs
in patients of the ARF/HF group. Data (N 
14) are referred to ultrafiltrate samples at 6,
12, and 24 hours (Fig. 1). For nonparametric
data, Spearman’s correlation test was per-
formed (r  0.5390; P  0.05).
Fig. 5. Effects of IL-8-priming on FMLP-
stimulated CL activity. PMNs (2  106) were
challenged with 10 to 4000 pg/mL IL-8 alone
with FMLP (final concentration 0.75 mol/L)
after preincubation for 10 minutes at 37C
with 10 to 4000 pg/mL IL-8 in the presence or
absence of anti-IL-8 blocking mAb 100 g/mL.
Results are expressed as a percentage varia-
tion of its own. Values represent means 
SEM of three experiments in duplicate. Sym-
bols are: ( ) IL-8  FMLP; ( ) IL-8 alone;
() IL-8  mAb anti-IL-8  FMLP.
Fig. 6. Effect of inhibitors on the CL priming
activity of the PMNs in the ultrafiltrates of the
ARF/HF and control/HF groups. PMNs were
preincubated with ultrafiltrate 100 L in pres-
ence of 100 g/mL selected mAb anti-IL-8 or
anti-IL-10, or of 1 mol/L WEB 2170 (a con-
centration that completely abrogated CL in-
duced by 10 ng/mL of synthetic PAF) and then
were stimulated with 0.75 mol/L FMLP. Data
are expressed as median with 25th and 75th
percentiles. The boxes enclose the inter-
quartile range and the median (open square
in each box), while whiskers enclose the range
(min-max value). The Mann-Whitney test was
performed in each group between UF 
FMLP versus samples pretreated with mAb or
WEB2170. Symbols are: () ultrafiltrate alone;
( ) UF FMLP; () mAb anti-IL-8UF
FMLP; ( ) WEB2170  UF  FMLP; ( )
mAb anti-IL-10  UF  FMLP.
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Fig. 7. Effect of the mAb anti-IL-8 on CL
priming activity in PMNs of sera from the
ARF/HF group. PMNs were preincubated
with serum (prefilter or postfilter, at T0 and
T4) 20 L in the presence of the selected mAb
anti-IL-8 100 g/mL (for more details, see the
Methods section) and then stimulated with
FMLP 0.75 mol/L. Data refer to septic pa-
tients of the ARF/HF group (N  4) and are
expressed as median with 25th and 75th per-
centiles. The boxes enclose the interquartile
range and the median (open square in each
box), while whiskers enclose the range (min-
max value). The Mann-Whitney test was per-
formed at each time point (T0 and T4) before
and after serum filtration. Symbols are: ( )
serum FMLP; () mAb anti-IL-8  serum 
FMLP.
with a worsening of clinical outcome [34]. In patients of ultrafiltration and IL-8 concentrations of ultrafiltrate
correlated with the CL priming activity. Moreover, anti-with trauma at risk of developing multiple organ failure,
PAF and IL-8 that appeared sequentially in the circula- IL-8 blocking antibodies significantly reduced the PMN
priming activity in the ultrafiltrates of septic patients,tion were indicated as potential mediators of priming
the circulating PMNs [9]. On the other hand, IL-8 was suggesting that the enhanced PMN priming activity ul-
trafiltered is mainly due to IL-8. Due to its high porosity,present in a high concentration in septic shock [2, 5, 26,
27, 32, 33], and in patients with trauma, IL-8 has been the polysulfone membrane can remove low-molecular-
weight proteins, such as IL-8, an 8 kD molecule. Studiessuggested to be an early biochemical marker predicting
the onset of MODS [9]. have shown that proteins in this size range are removed
both by transmembranous action (diffusion and convec-There was enhanced PMN priming to subsequent stim-
ulation with FMLP in sera of septic patients with acute tion) and by absorption to the membrane [35].
The amount of serum and ultrafiltered PMN primingrenal failure with respect uremic controls. This enhance-
ment was concomitant with an increased concentration activity in the control uremic patients, as well as the con-
centration of IL-8, was significantly lower than in septicof PAF and IL-8 in blood. Therefore, we studied whether
the PMN priming activity was detectable in the ultrafil- patients, and CL PMN priming activity was not inhibited
by IL-8 mAb. These results indicate that in uremic pa-trates of septic patients and whether this could account
for the ultrafiltration of PAF or IL-8. The results obtained tients on hemofiltration, the PMN priming activity, also
present in normal healthy serum (Fig. 1), cannot be ac-indicated that PMN priming activity was detectable in
the ultrafiltrate, suggesting that factors present in plasma counted for by IL-8, and exclude that the hemofiltration
procedure itself causes a substantial IL-8 production byand responsible for this biological activity were removed
by ultrafiltration. A significant amount of PAF was eluted membrane-blood contact.
The issue of the capability of hemofiltration to removefrom the filter at the end of the four-hour treatment.
Polysulfone possesses a hydrophobic nature and pro- cytokines is controversial. It has been argued that the
amounts of mediators detected in the ultrafiltrate couldmotes both nonspecific interactions between the mem-
brane and hydrophobic amino acid residues within pro- not be sufficiently relevant to determine an effective
body clearance. However, recently a significant removalteins [35], and adsorption on the membrane of PAF, a
lipid mediator of hydrophobic nature bound in blood to during the first hours of hemofiltration has been demon-
strated for TNF, IL-6, and C3adesArg [3–5]. In the presentalbumin at four binding sites [36, 37]. However, the study
on PAF ultrafiltration indicated that it was minimally study, we observed a significant mass transfer of IL-8
after four hours of hemofiltration. These data suggestultrafiltered. The failure of a PAF receptor antagonist
to inhibit PMN priming activity suggests that the PMN that low-molecular-weight mediators may be effectively
removed at the beginning of hemofiltration treatment.priming activity recovered in the ultrafiltrates cannot be
ascribed to the elimination of this mediator. In contrast, In conclusion, the results of the present study indicate
that PMN priming activity, which is enhanced in septica significant amount of IL-8 was ultrafiltered; the serum
concentrations of IL-8 were reduced after four hours patients with ARF, can be significantly ultrafiltered dur-
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serves as a priming bed for circulating neutrophils that provokeing hemofiltration and suggest that IL-8 is the main medi-
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